dpp-4 inhibitors vs. glp-1 agonist Role of Dipeptidyl Peptidase 4 in Antidiabetic Treatment Renoprotective Effects of DPP-4 Inhibitors

Can targeting the incretin pathway dampen RAGE-mediated events in diabetic nephropathy

In recent years, GLP-1 medications have become a focal point in the medical community due to their innovative treatment mechanisms, significant therapeutic efficacy, and broad development prospects

The combination of fiber, healthy fats, and lean protein creates multiple opportunities for nutrient-stimulated hormone responses throughout the day

This phenomenon is also not thought to be a direct toxic effect of the drug itself, but rather a known risk associated with rapid and substantial improvement in glycemic control, which can also be observed with the initiation of intensive insulin therapy

Thiazolidinediones (TZDs): Enhance peripheral insulin sensitivity